BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Results of Operations and Financial Condition

BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02. Results of Operations and Financial Condition.

On April 27, 2017, Bristol-Myers Squibb Company (the Company)
issued a press release announcing its financial results for the
first quarter of 2017. A copy of the press release is furnished
as Exhibit 99.1 to this report and incorporated herein by
reference. Also furnished and incorporated by reference as
Exhibit 99.2 is certain supplemental information posted on the
Companys website at
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Press release of Bristol-Myers Squibb Company dated
April 27, 2017.
Certain supplemental information posted on
Bristol-Myers Squibb Companys website at
not included in the press release.


Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.


BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) closed its last trading session 00.00 at 940.00 with shares trading hands.

An ad to help with our costs